These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 819576)

  • 1. A new Pseudomonas vaccine: preliminary trial on human volunteers.
    Jones RJ; Roe EA; Lowbury EJ; Miler JJ; Spilsbury JF
    J Hyg (Lond); 1976 Jun; 76(3):429-39. PubMed ID: 819576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trials of a polyvalent pseudomonas vaccine in burns.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1979 Nov; 2(8150):977-82. PubMed ID: 91774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.
    Jang IJ; Kim IS; Park WJ; Yoo KS; Yim DS; Kim HK; Shin SG; Chang WH; Lee NG; Jung SB; Ahn DH; Cho YJ; Ahn BY; Lee Y; Kim YG; Nam SW; Kim HS
    Vaccine; 1999 Jan; 17(2):158-68. PubMed ID: 9987150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
    Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
    Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ
    J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
    Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of early protective responses induced by pseudomonas vaccines.
    Jones RJ
    J Hyg (Lond); 1972 Jun; 70(2):343-51. PubMed ID: 4503873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of three serological tests for detection of antibody to Pseudomonas aeruginosa in human sera.
    Pitt TL; Todd HC; Mackintosh CA; Im SW
    Eur J Clin Microbiol; 1985 Apr; 4(2):190-6. PubMed ID: 3924607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active and passive immunization against Pseudomonas aeruginosa infection of burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1983 Jul; 9(6):433-9. PubMed ID: 6412970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers.
    Martindale JJ; Ganzinger U; Steinmüller W; Millendorfer A; Ambrosch F; Kollaritsch H; Wiedermann G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 May; 268(3):376-85. PubMed ID: 3136608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-linked immunosorbent assay (ELISA) and a passive haemagglutination test (PHT) for the detection of pseudomonas antibodies in burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1985 Apr; 11(4):252-8. PubMed ID: 3924353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1980 Dec; 2(8207):1263-5. PubMed ID: 6108445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Testing the protective effectiveness of vaccines against infection with Pseudomonas aeruginosa in mink (Lutreola vison)].
    Dousek J; Sourek J; Dvorák R; Hartman V; Vejlupek O
    Vet Med (Praha); 1986 Nov; 31(11):695-704. PubMed ID: 3097914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.